ITGB3/CD61: a hub modulator and target in the tumor microenvironment
- 1 January 2019
- journal article
- review article
- Vol. 11 (12) , 7195-7208
Abstract
Beta 3 integrin (ITGB3), also known as CD61 or GP3A, is one of the most widely studied components in the integrin family. As an adhesion receptor on the cell surface, ITGB3 participates in reprogramming tumor metabolism, shaping the stromal and immune microenvironment, facilitating epithelial to mesenchymal transition (EMT) and endothelial to mesenchymal transition (End-MT) and maintaining tumor stemness, etc. Recent studies proposed various intervention strategies against ITGB3 and have achieved promising outcomes in several types of tumor. Here, we review the adaption response and cellular crosstalk in the tumor microenvironment mediated by ITGB3, as well as its upstream and downstream signaling pathways. Lastly, we focus on the inhibitors of ITGB3, ultimately indicating that ITGB3 is a promising target in the tumor microenvironment.Keywords
This publication has 105 references indexed in Scilit:
- MFGE8 inhibits inflammasome-induced IL-1β production and limits postischemic cerebral injuryJournal of Clinical Investigation, 2013
- Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancerInvestigational New Drugs, 2012
- Macrophage plasticity and polarization: in vivo veritasJournal of Clinical Investigation, 2012
- aV integrins and TGF‐β‐induced EMT: a circle of regulationJournal of Cellular and Molecular Medicine, 2012
- Proteomics Identification of ITGB3 as a Key Regulator in Reactive Oxygen Species-induced Migration and Invasion of Colorectal Cancer CellsMolecular & Cellular Proteomics, 2011
- CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin–TGFβ signalingOncogene, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Integrin Structure, Activation, and InteractionsCold Spring Harbor Perspectives in Biology, 2011
- Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortiumInvestigational New Drugs, 2010
- An integrin αvβ3–c-Src oncogenic unit promotes anchorage-independence and tumor progressionNature Medicine, 2009